RecruitingPhase 3

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Canada330 participantsStarted 2025-11-10

Plain-language summary

This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);
✓. Patient or healthcare proxy provide informed consent.

Exclusion criteria

✕. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \< 90 days according to the treating team;
✕. Patient requires intensive care but has a do not resuscitate order precluding transfer;
✕. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);
✕. Organism tests as rifampin resistant;
✕. History of hypersensitivity/anaphylaxis or severe adverse reaction to rifampin;
✕. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \[with as-needed consultation from experts from pharmacy and/or internal medicine/geriatrics for potential deprescribing\];
✕. Child Pugh Class C cirrhosis;
✕. Clinician deems rifampin to be mandatory;

What they're measuring

Treatment failure

Timeframe: 180 days

Trial details

NCT IDNCT07253688

SponsorTodd C. Lee MD MPH FIDSA

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-12

Contact for this trial

Lina Petrella

514-934-1934 lina.petrella@affiliate.mcgill.ca

View on ClinicalTrials.gov More Staphylococcus Aureus Endocarditis trials